Egrifta (Tesamorelin) Relationship and Intimacy Impact
At a glance
- Libido / Not established; label reports no clinically significant change in LH, TSH, ACTH or prolactin [1]
- Approved use / Reduction of excess abdominal fat in HIV-associated lipodystrophy [1]
- Visceral fat, Study 1 / Fell 15.2% vs rose 5.0% on placebo at 26 weeks (412 patients) [2]
- Visceral fat, pooled phase 3 / -24 cm2 vs +2 cm2 at week 26 (806 patients) [3]
- Injection-site reactions / 25% vs 14% on placebo, first 26 weeks [1]
- Fluid retention / Edema, joint pain and carpal tunnel syndrome are labeled warnings [1]
- Pregnancy / Contraindicated; label says discontinue if pregnancy occurs [1]
- Off-treatment regain / Week 26 to 52 VAT change 0% and -5% on continued treatment vs +22% and +16% switched to placebo [1]
Is there any direct effect on libido or sexual function?
Tesamorelin is a growth hormone-releasing factor analog. It binds GRF receptors on pituitary somatotroph cells and stimulates release of the body's own growth hormone, which raises IGF-1 and IGFBP-3 [1]. It is a peptide, not growth hormone and not a steroid [1].
The label reports no clinically significant changes in TSH, LH, ACTH or prolactin in patients who received Egrifta during trials [1]. Those are pituitary hormones. Sexual desire, arousal, orgasm and erectile function were not reported as outcomes [1][2].
One related label note: growth hormone may alter the clearance of drugs metabolized by CYP450 liver enzymes (the label names corticosteroids, sex steroids, anticonvulsants and cyclosporine as examples), and the label advises monitoring when Egrifta is given with such drugs [1].
What the trials changed: less abdominal fat
In Study 1, 412 HIV-infected adults (86% men) with excess abdominal fat received tesamorelin 2 mg or placebo subcutaneously daily for 26 weeks. Visceral adipose tissue on CT fell 15.2% on tesamorelin and rose 5.0% on placebo, with triglycerides, the total-to-HDL cholesterol ratio and IGF-1 all moving in the treated group (P<0.001 for all) [2]. Study 2, with 404 patients randomized 2:1, found visceral fat down 10.9% versus 0.6% on placebo at 6 months (P<0.0001) [4]. The pooled phase 3 analysis of 806 patients put the week-26 change at -24 cm2 versus +2 cm2, a treatment effect of -15.4% [3].
Study 1 also assessed self-assessed body image as a secondary endpoint [2]. It did not show whether tesamorelin changed relationships or intimacy.
A review of 57 studies in healthy women concluded that body-image issues can affect all domains of sexual functioning, with self-consciousness and body-related thoughts interfering with sexual response and experience as well as sexual behavior and avoidance [5]. That review did not test tesamorelin or people with HIV lipodystrophy.
What the label says a partner might notice
Several labeled effects are physical and visible.
Injection sites. Injection-site reactions occurred in 25% of tesamorelin-treated patients versus 14% on placebo during the first 26 weeks, including erythema, itching, pain, irritation and bruising [1]. Injections go into the abdomen, and the label says to rotate sites to different areas of the abdomen to reduce these reactions [1].
Fluid retention. The label lists edema, joint pain and carpal tunnel syndrome as fluid-retention effects, described as either transient or resolving with discontinuation of treatment [1]. Joint pain was reported in 13% versus 11% on placebo, peripheral edema 6% versus 2%, and muscle pain 6% versus 2% [1].
Hypersensitivity. Reactions occurred in 4% of patients in trials and included itching, redness, flushing, hives and rash; the label says patients should seek prompt medical attention and that treatment should be stopped immediately if a reaction is suspected [1].
Glucose. HbA1c of 6.5% or higher developed in 5% on tesamorelin versus 1% on placebo by week 26, a hazard ratio of about 3.3 (95% CI 1.4 to 9.6), and the label calls for glucose evaluation before and during therapy [1].
IGF-1. Among patients treated for 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS; among those treated for 52 weeks, 34% and 23% [1]. The label states that the effects of prolonged IGF-1 elevation are unknown and calls for monitoring, with consideration of discontinuing if levels stay high, particularly when fat loss is not robust [1].
Pregnancy and what the label says
Egrifta is contraindicated in pregnancy [1]. In rats, tesamorelin given during organogenesis produced hydrocephalus in offspring at roughly two and four times the clinical dose based on drug exposure [1]. The label says to discontinue Egrifta if pregnancy occurs [1].
On lactation, the label notes CDC advice that HIV-infected mothers in the United States should not breastfeed, to avoid postnatal transmission of HIV-1, and states that mothers should not breastfeed if they receive Egrifta [1].
The daily routine
The two current products differ, and the labels say they are not substitutable [6]. Egrifta SV is 1.4 mg (0.35 mL of the reconstituted 2 mg per 0.5 mL solution) injected subcutaneously into the abdomen once daily; the label says to reconstitute with Sterile Water for Injection, administer immediately, and discard any leftover solution [1]. Egrifta WR is 1.28 mg (0.16 mL of an 8 mg/mL solution), reconstituted with 1.3 mL of Bacteriostatic Water for Injection; one vial supplies seven daily doses, and the remainder is discarded 7 days after mixing [6].
If treatment stops
Among patients in the extension studies who switched to placebo after 26 weeks, visceral fat increased by 22% in Study 1 and 16% in Study 2, while it changed by 0% in Study 1 and decreased 5% in Study 2 in patients who continued tesamorelin [1].
The label's limitations of use say to consider the risk and benefit of continuing in patients who have not had a reduction in visceral adipose tissue, note that long-term cardiovascular safety has not been established, and state that the drug is not indicated for weight loss because its effect on weight is neutral [1].
Frequently asked questions
Does tesamorelin increase or decrease sex drive?
Can tesamorelin help with erectile dysfunction?
How much abdominal fat change did the trials measure?
Will a partner notice the injections?
What happens to abdominal fat if I stop Egrifta?
Is Egrifta an option during pregnancy?
References
Show all 6 referencesHide references
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70.
- Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304.
- Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-22.
- Woertman L, van den Brink F. Body image and female sexual functioning and behavior: a review. J Sex Res. 2012;49(2-3):184-211.
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label